SCHEMBL3014677

SCHEMBL3014677

Cc1cc(C)cc(-c2csc(N3CCC(S(=O)(=O)c4cccc(C(F)(F)F)c4)CC3)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.51
RAB9A P51151 4/20 0.49
NPC1 O15118 3/20 0.49
CTSS P25774 1/20 0.47
RAF1 P04049 1/20 0.43
BRAF P15056 1/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
SMN1; SMN2 Q16637 6/20 0.42
KCNQ1 P51787 1/20 0.42
MAPT P10636 2/20 0.41
POLB P06746 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
KDM1A O60341 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006338 0.94 AR (0.55) ARRAB9ANPC1CTSSRAF1
SCHEMBL3019382 0.93 SMN1; SMN2 (0.51) ARRAB9ANPC1CTSSRAF1
SCHEMBL3016128 0.90 CTSS (0.47) ARRAB9ANPC1CTSSRAF1
SCHEMBL3008360 0.90 AR (0.52) ARRAB9ANPC1CTSSRAF1
SCHEMBL3005719 0.90 AR (0.52) ARRAB9ANPC1CTSSRAF1
SCHEMBL3017305 0.90 AR (0.56) ARRAB9ANPC1CTSSKMT2A
SCHEMBL3005106 0.89 AR (0.52) ARRAB9ANPC1CTSSRAF1
SCHEMBL3017314 0.88 MAPT (0.49) ARRAB9ANPC1CTSSKMT2A
SCHEMBL3016070 0.88 CTSS (0.48) ARRAB9ANPC1CTSSRAF1
SCHEMBL3010240 0.88 RAB9A (0.47) ARRAB9ANPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.